Literature DB >> 10472531

Renal clearance of branched-chain L-amino and 2-oxo acids in maple syrup urine disease.

P Schadewaldt1, H W Hammen, A C Ott, U Wendel.   

Abstract

In maple syrup urine disease (MSUD), branched-chain L-amino (BCAA) and 2-oxo acids (BCOA) accumulate in body fluids owing to an inherited deficiency of branched-chain 2-oxo acid dehydrogenase complex activity. In MSUD, little information is available on the significance of urinary disposal of branched-chain compounds. We examined the renal clearance of leucine, valine, isoleucine and alloisoleucine, and their corresponding 2-oxo acids 4-methyl-2-oxopentanoate (KIC), 3-methyl-2-oxobutanoate (KIV), (S)-(S-KMV), and (R)-3-methyl-2-oxopentanoate (R-KMV), using pairs of plasma and urine samples (n = 63) from 10 patients with classical MSUD. The fractional renal excretion of free BCAA was in the normal range (< 0.5%) and independent of the plasma concentrations. The excretion of bound (N-acylated) BCAA was normal and not significantly dependent on the BCAA plasma concentrations. The fractional renal excretion of BCOA was in the order KIC << KIV < R-KMV < or = S-KMV (range (%): KIC 0.1-25; KIV 0.14-21.3; S-KMV 0.26-24.6; R-KMV 0.1-35.9), significantly correlated with the KIC plasma concentrations, and generally higher than that of the related BCAA. The results show that the renal excretion of free BCAA as well as of the acylated derivatives is negligible. The renal excretion of BCOA, however, to some extent counteracts increases in BCAA concentrations and thus contributes to the lowering of total BCAA pools in MSUD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472531     DOI: 10.1023/a:1005540016376

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  32 in total

1.  Maple syrup urine disease: branched-chain keto-aciduria.

Authors:  J DANCIS; M LEVITZ; R G WESTALL
Journal:  Pediatrics       Date:  1960-01       Impact factor: 7.124

2.  Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination.

Authors:  E Treacy; C L Clow; T R Reade; D Chitayat; O A Mamer; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  On the mechanism of L-alloisoleucine formation: studies on a healthy subject and in fibroblasts from normals and patients with maple syrup urine disease.

Authors:  P Schadewaldt; H W Hammen; C Dalle-Feste; U Wendel
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  Branched-chain alpha-keto acids isolated as oxime derivatives: relationship to the corresponding hydroxy acids and amino acids in maple syrup urine disease.

Authors:  G Lancaster; O A Mamer; C R Scriver
Journal:  Metabolism       Date:  1974-03       Impact factor: 8.694

Review 5.  Hydrolysis of proteins.

Authors:  R L Hill
Journal:  Adv Protein Chem       Date:  1965

6.  Determination of (S)- and (R)-2-oxo-3-methylvaleric acid in plasma of patients with maple syrup urine disease.

Authors:  U Wendel; G Even; U Langenbeck; P Schadewaldt; W Hummel
Journal:  Clin Chim Acta       Date:  1992-06-15       Impact factor: 3.786

7.  Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past.

Authors:  N T Price; V N Jackson; A P Halestrap
Journal:  Biochem J       Date:  1998-01-15       Impact factor: 3.857

8.  Alpha-keto and alpha-hydroxy branched-chain acid interrelationships in normal humans.

Authors:  L J Hoffer; A Taveroff; L Robitaille; O A Mamer; M L Reimer
Journal:  J Nutr       Date:  1993-09       Impact factor: 4.798

9.  New conjugated urinary metabolites in intermediate type maple syrup urine disease.

Authors:  L Hagenfeldt; A S Naglo
Journal:  Clin Chim Acta       Date:  1987-10-30       Impact factor: 3.786

10.  Assessment of tubular reabsorption of sodium, glucose, phosphate and amino acids based on spot urine samples.

Authors:  R Rossi; S Danzebrink; K Linnenbürger; D Hillebrand; M Grüneberg; V Sablitzky; T Deufel; K Ullrich; E Harms
Journal:  Acta Paediatr       Date:  1994-12       Impact factor: 2.299

View more
  4 in total

1.  Renal excretion of galactose and galactitol in patients with classical galactosaemia, obligate heterozygous parents and healthy subjects.

Authors:  P Schadewaldt; S Killius; L Kamalanathan; H W Hammen; K Strassburger; U Wendel
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

2.  Duration of extracorporeal therapy in acute maple syrup urine disease: a kinetic model.

Authors:  Véronique Phan; Marie-José Clermont; Aicha Merouani; Catherine Litalien; Marisa Tucci; Marie Lambert; Grant Mitchell; Philippe Jouvet
Journal:  Pediatr Nephrol       Date:  2006-03-04       Impact factor: 3.714

3.  Classical maple syrup urine disease and brain development: principles of management and formula design.

Authors:  Kevin A Strauss; Bridget Wardley; Donna Robinson; Christine Hendrickson; Nicholas L Rider; Erik G Puffenberger; Diana Shellmer; Diana Shelmer; Ann B Moser; D Holmes Morton
Journal:  Mol Genet Metab       Date:  2010-01-12       Impact factor: 4.797

4.  Cytoskeletal stability and metabolic alterations in primary human macrophages in long-term microgravity.

Authors:  Svantje Tauber; Beatrice A Lauber; Katrin Paulsen; Liliana E Layer; Martin Lehmann; Swantje Hauschild; Naomi R Shepherd; Jennifer Polzer; Jürgen Segerer; Cora S Thiel; Oliver Ullrich
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.